Ginkgo biloba extract for early diabetic retinopathy
Part of Eyes & vision clinical trials.
This study tests a ginkgo biloba extract (EGb761) to see if it can help prevent or slow early diabetic retinopathy. Participants will receive the extract or a placebo (inactive pill), and their eye health will be monitored over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have diabetes with a recent HbA1c test of 13% or lower.
- You have had diabetes for at least 5 years, and either no signs of diabetic retinopathy or only early (stage I or II) retinopathy without swelling in the center of the retina.
- You have not had laser treatment, injections, or surgery on your eyes for diabetes.
- You have not taken ginkgo biloba extract in the past 12 months.
- You do not have severe heart, lung, liver, or kidney problems, and your blood pressure is under control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether an experimental eye drop can slow or treat early-stage diabetic retinopathy. If you have diabetes-related vision changes, this treatment might help prevent the condition from getting worse.
This study looks at how well surgery called vitrectomy works for people with severe nonproliferative diabetic retinopathy (NPDR), a condition where high blood sugar damages the retina. The trial aims to see if this surgery can improve vision and outcomes.
This early-phase study tests a treatment aimed at preventing or slowing early diabetic eye disease in people with mild, early changes. You may be considered if your diabetes is moderately controlled and your eye tests show early warning signs.
This study tests a new approach aimed at improving diabetic eye disease (diabetic retinopathy). It may help by changing inflammation and related processes in the eye, especially in people who have diabetes and eye changes.
This trial tests a new medicine, RRG001, given after vitrectomy surgery for severe diabetic eye disease. It aims to see if the drug is safe and helps prevent vision loss.
This study looks at how images and other tests of the eye can help predict diabetic retinopathy, an eye problem caused by diabetes that can lead to vision loss. If you have diabetes, your eye health will be monitored closely. If you do not, you may participate as a healthy comparison.
Hear when a new Non-proliferative Diabetic Retinopathy (NPDR) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.